(Total Views: 570)
Posted On: 03/19/2021 7:00:17 PM
Post# of 155004
28D mortality
overall (mITT) N=384
LL 53/259 = 20.5%
PB 27/125 = 21.6%
with SOC, N=309
LL 34/205 = 16.6%
PB 24/104 = 23.1%
without SOC, N=75
LL 19/54 = 35.2%
PB 3/21 = 14.3%
If the trial were just those getting SOC, we would have an easy EUA.
The numbers speak for themselves, and I won't repeat the phrase you don't want to hear about how they did with LL, but if we can figure out what might be different about the 75 (other than they didn't get any other common treatment), we can exclude them from CD16 and have a much better chance at success. Maybe it will be enough to make sure LL is added on to something else and not used alone.
Looking forward to hear what the FDA and CYDY say about EUA and CD16 trial.
overall (mITT) N=384
LL 53/259 = 20.5%
PB 27/125 = 21.6%
with SOC, N=309
LL 34/205 = 16.6%
PB 24/104 = 23.1%
without SOC, N=75
LL 19/54 = 35.2%
PB 3/21 = 14.3%
If the trial were just those getting SOC, we would have an easy EUA.
The numbers speak for themselves, and I won't repeat the phrase you don't want to hear about how they did with LL, but if we can figure out what might be different about the 75 (other than they didn't get any other common treatment), we can exclude them from CD16 and have a much better chance at success. Maybe it will be enough to make sure LL is added on to something else and not used alone.
Looking forward to hear what the FDA and CYDY say about EUA and CD16 trial.
(1)
(0)
